



**VGX Pharmaceuticals Strengthens Management Team with Two New Appointments: Dorothy Peterson Appointed as Director of Quality  
Debra A. Bacino Appointed as Controller**

**Blue Bell, PA – May 2, 2007 –**

VGX Pharmaceuticals announced the appointment of two senior biotechnology industry professionals to strengthen the company's manufacturing operations and finance. Dorothy Peterson will serve as Director of Quality and Debra A. Bacino, CPA will serve as Controller for VGX Pharmaceuticals.

Ms. Peterson comes to VGX with over 20 years experience in the medical device industry complying with FDA regulations in both start up and established organizations. Ms. Peterson recently relocated to Houston, TX from San Diego, CA where she was VP of Operations at Qualigen, Inc. which included the responsibility for quality and regulatory affairs. While at Qualigen, she successfully submitted several 510(k) applications and led the company through multiple regulatory agency audits including ISO 13485 to gain the CE mark. Prior to Qualigen, Ms. Peterson was at Hybritech, Inc. (a subsidiary of Beckman-Coulter) where she held multiple positions in both the quality and manufacturing organizations. Ms. Peterson received her Bachelor of Science in Biology from Sam Houston State University in Huntsville, Texas. She is also a member of the Regulatory Affairs Professional Society.

Ms. Bacino has over 25 years of financial experience focused in both major pharmaceutical companies as well as biotechnology. She served as Controller for Eximias Pharmaceutical Corporation, a development stage biotechnology company, where she was responsible for building and managing the corporate financial and human resource infrastructure. Prior to Eximias, Ms. Bacino was Plant Controller for a Novartis Consumer Health production facility. Before Novartis, she maintained a successful career with Rhône-Poulenc Rorer in increasingly responsible positions in divisional finance, corporate finance, financial budgeting, planning and analysis, auditing and general accounting. Ms. Bacino received her Bachelor of Arts degree in Mathematics from West Chester University. She is a Certified Public Accountant licensed in the state of Pennsylvania.

Dr. J. Joseph Kim, President and CEO of VGX commented, "We are very pleased to have Dorothy and Debra join VGX as we look to expand and grow our business operations by recruiting key professionals. Dorothy brings a wealth of operational, quality and regulatory experience and further strengthens our ability to provide our clients with world-class cGMP manufacturing services. Debra strengthens our financial operations by bringing in broad accounting and corporate finance experience as we get closer to our overall goal of becoming a publicly traded global biopharmaceuticals company."

**Cautionary Factors That May Affect Future Results** - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on [www.vgxp.com](http://www.vgxp.com) as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

### **About VGX Pharmaceuticals**

VGX Pharmaceuticals is a biopharmaceutical company with small molecules and biologics product candidates for the treatment of infectious diseases, cancer and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection, both of which are currently in Phase II clinical trials. In addition, Phase I clinical trials will be initiated in 2007 for VGX-150 for the treatment of Melanoma and VGX-1027 for inflammatory diseases. VGX's research pipelines include new generation of DNA vaccines and therapeutics as well as CELLECTRA™, a proprietary DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at [www.vgxp.com](http://www.vgxp.com).

**Company Contact:**

Kevin W. Rassas

Senior Vice President

Tel. 267.440.4208

Fax 267.440.4242

E-mail: [Rassas@vgxp.com](mailto:Rassas@vgxp.com)

[www.vgxp.com](http://www.vgxp.com)